Tassal Group shares soar 9% on half-year results

The Tassal Group Limited (ASX: TGR) share price has jumped 9% higher today following the release of its 1H20 results.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Tassal Group Limited (ASX: TGR) share price has rocketed more than 9% today following the release of its half-year results for the 6 months to December 2019 (1H20).

At the time of writing, Tassal shares are going for $4.50 a piece.

What did Tassal announce?

Tassal has today announced 1H20 revenue of $274.49 million, which represents a drop of 15.8% on the prior corresponding period (pcp).

Statutory net profit after tax (NPAT) was up 24.3% to $40.82 million, while operating cash flow was down 48.6% to $40.97 million. Tassal ended the period with cash held of $15.33 million, which was down from $17.81 million in 1H19.

This cash flow was in line with expectations and reflected the decision to leave the salmon in the water longer to grow (and therefore feed more). This resulted in lower overall sales revenue (through targeting a reduction in sales for the lower value export and less profitable domestic sales), however, the tactic is set to underpin strong harvest and sales in 2H20 and FY21.

Salmon

Tassal's 1H20 strategy was to grow operating earnings before interest, tax, depreciation and amortisation (EBITDA) $/kg while driving harvest and sales in 2H20 to deliver expected earnings growth in FY20 and beyond.

Tassal posted a 15.5% increase in its salmon operating EBITDA $/Kg (Pre AASB 16) to $3.44/kg. An average harvest size increase per hog of 4.8kg was seen, 2.1% larger than 1H19. Tassal also reported a 15.5% increase in live fish over the prior corresponding period (pcp).

Total salmon sales were down 14.4%, with domestic salmon sales increasing 0.6% and export sales decreasing 45.9%. Export sales make up 20.3% of Tassal's total sales.

Prawns

Tassal confirmed its prawn biomass harvest is on track to deliver targeted circa 2,400 tonnes in 2H20 for FY20. The group advised its prawn earnings for 2H20 are effectively represented as a self generating and regenerating asset value of $15.4 million, as this stock is planned to be harvested and sold before 30 June 2020. The company is targeting an EBITDA $/Kg of $6.00/kg in FY20 in the prawns business.

Also noted was an increase in prawn biomass over the pcp of 498.9% to 557 tonnes.

Dividend

Tassal announced no change to its interim dividend, declaring a dividend of 9 cents per share, franked at 25%, to be paid on Tuesday 31 March. 

Tassal's 2H20 outlook

Tassal expects positive market dynamics for both salmon and prawns to continue, with strong pricing and favourable competitive positioning for prawns in the short to medium term.

The group's salmon biomass growth is currently exceeding expectations, which should support optimised pricing to provide increasing operating EBITDA $/kg. Tassal also notes a transitioning of supply for the continuation of more sales into the domestic market.

Further investment in both salmon and prawn operations is set to continue to underpin long-term growth with a total capital expenditure, including the acquisition of Exmoor Station, of $156 million expected in FY20.

Motley Fool contributor Michael Tonon has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Share Gainers

3 ASX 200 stocks storming higher in this week's sinking market

Investors have sent these three ASX 200 stocks soaring this week. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Market News

Why Aeris Resources, Netwealth, Nova Minerals, and Paragon Care shares are dropping today

These shares are under pressure on Friday. Let's find out why.

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Gainers

Why 4DMedical, Develop Global, EOS, and Maas shares are racing higher today

These shares are ending the week on a high. But why?

Read more »

A man leans forward over his phone in his hands with a satisfied smirk on his face although he has just learned something pleasing or received some satisfying news.
Share Market News

Downer EDI wins $870m NZ highway maintenance contracts: What investors need to know

Downer EDI wins major New Zealand state highway maintenance contracts worth NZ$870 million, expanding its infrastructure portfolio.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Ord Minnett names 2 ASX 200 shares to buy for massive returns

The broker sees a lot of value in these big names. Here's what it is recommending.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 657% in a year, 4DMedcial shares rocketing another 20% today on big US news

ASX investors can’t get enough of 4DMedical shares today. Let’s see why.

Read more »